Medicine
Glipizide 2.5 mg extended-release tablet
Glipizide 2.5 mg extended-release tablet is a generic prescription medicine for oral use, made by 7 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77º F),. The tablets should be protected from…
Key facts
- Active ingredient (INN)
- Glipizide
- Brand
- Sold under the generic name
- Strength
- 2.5 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 30 tablets, 90 tablets, 30 blister pack and 10 more
- Manufacturers
- Aurobindo PharmaIndiaPreferred PharmaceuticalsRemedyrepackBryant Ranch PrepackAmerican Health PackagingNorthStar RxRising Pharma Holdings
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77º F),. The tablets should be protected from moisture and humidity.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10BB07 Glipizide
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 24 April 2017
- Identifiers
- RxCUI 310489, 314006, 315107DailyMed set ID 0338aff9-29f9-405e-b516-06ef4b863863, aaf029d3-027e-4ae8-8ec5-3a4c16f9bd28, 4632b4ec-d2f1-40cc-8ef4-256413d8dbec +5NDC 71335-1042, 60687-768, 68788-8487 +5Application ANDA204720, ANDA206928, ANDA203499
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, extended release in 1 bottle | 59651-780-30 | Aurobindo PharmaIndia | 3 March 2023 |
| 30 tablet, film coated, extended release in 1 bottle, plastic | 64980-279-03 | Rising Pharma Holdings | 24 April 2017 |
| 30 tablet, film coated, extended release in 1 blister pack | 70518-2308-0 | Remedyrepack | 11 September 2019 |
| 90 tablet, film coated, extended release in 1 bottle, plastic | 70518-2308-1 | Remedyrepack | 27 August 2025 |
| 90 tablet, extended release in 1 bottle, plastic | 70518-3645-1 | Remedyrepack | 15 July 2024 |
| 30 blister pack in 1 carton / 1 tablet, extended release in 1 blister pack | 60687-768-21 | American Health Packaging | 14 February 2024 |
| 30 tablet, film coated, extended release in 1 bottle | 71335-1042-1 | Bryant Ranch Prepack | 8 January 2019 |
| 60 tablet, film coated, extended release in 1 bottle | 71335-1042-2 | Bryant Ranch Prepack | 8 January 2019 |
| 30 tablet, extended release in 1 bottle | 16714-894-01 | Northstar Rx | 1 December 2018 |
| 100 tablet, film coated, extended release in 1 bottle, plastic | 68788-8487-1 | Preferred Pharmaceuticals | 19 July 2023 |
| 30 tablet, film coated, extended release in 1 bottle, plastic | 68788-8487-3 | Preferred Pharmaceuticals | 19 July 2023 |
| 60 tablet, film coated, extended release in 1 bottle, plastic | 68788-8487-6 | Preferred Pharmaceuticals | 19 July 2023 |
| 90 tablet, film coated, extended release in 1 bottle, plastic | 68788-8487-9 | Preferred Pharmaceuticals | 19 July 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 8 May 1984 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Glipizide
Clinical summary
Glipizide is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is available as tablets and extended-release tablets for oral use. MedsAcross supplies Glipizide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GlipizideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Glucotrol XL prescribing information (Roerig) · U.S. National Library of Medicine, DailyMed
Need Glipizide 2.5 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.